NEW YORK, May 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20 a.m. Eastern ...

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20 a.m. Eastern ...

NEW YORK, May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=81730&from=4CLASS PERIOD: December 1, 2023 to April 2 ...

LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, will be presenting at the iFX Expo, the World's largest online trading conference and tradeshow held on June 18 until June 20 in Limassol, Cyprus. https://cyprus2024.ifxexpo.com/The iFX Expo brings together thousands of C-Level Executives and Industry Peers from 120 countries. The Online Trading Platform Market wa ...

Group 1: Penny Stocks Overview - The penny stock market presents multiple overlooked investment opportunities, particularly with macroeconomic tailwinds expected in the second half of 2024, including potential interest rate cuts by the Fed [1] - Not all penny stocks are strong investments, but certain companies discussed have more positives than negatives, warranting attention [1] Group 2: Altimmune (ALT) - Altimmune is positioned as a promising player in the weight loss drug sector, particularly due to its pemvidutide, which results in a 25.5% decrease in lean muscle mass, significantly less than the nearly 40% decline associated with competitors' drugs [2][3] - The ability to maintain muscle mass during weight loss is crucial for health, especially in elderly populations, making muscle-preserving weight loss drugs a key area of interest [3] Group 3: Grab Holdings (GRAB) - Grab Holdings is emerging as a super app with strong revenue growth of 24%, resulting in sales of $653 million, and has narrowed its operating loss by $129 million [5] - The company has raised its 2024 EBITDA prediction from $180 million to a range of $250 to $270 million, reflecting confidence in its performance [5] - Grab's strategic focus on fintech is yielding lower payment costs and contributing to its growth in Southeast Asia [5] Group 4: Lithium Americas (LAC) - Lithium Americas is developing the Thacker Pass lithium deposit in Nevada, which is set to become the largest lithium project in history, with full production expected by 2028 [6] - The Thacker Pass deposit has an estimated mine life of over 40 years and has attracted significant investment, including $650 million from General Motors and a $2.26 billion loan from the Department of Energy [6] - There is potential for share prices to quadruple or quintuple in the next 12 to 18 months, indicating strong future growth prospects [7]

Mykola Sosiukin/iStock via Getty Images Altimmune Inc. (NASDAQ:ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Altimmune securities is from December 1, 2023, to April 26, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by July 5, 2024, to serve as lead plaintiff [1][4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company [2] - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2] Group 3: Allegations Against Altimmune - The lawsuit alleges that Altimmune made false and misleading statements regarding its lead product candidate, pemvidutide, particularly in relation to its efficacy and tolerability compared to competitors [3] - It is claimed that the results from the MOMENTUM trial were less significant than represented, impacting Altimmune's commercial prospects [3] - The lawsuit asserts that these misrepresentations led to an overstatement of Altimmune's potential for finding a strategic partner for pemvidutide [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1 - The class period for the allegations is from December 1, 2023, to April 26, 2024 [1]. - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [1]. Group 2 - The lawsuit also contends that Altimmune's public statements were materially false and misleading, impacting the company's perceived prospects for finding a strategic partner for pemvidutide [1]. - Shareholders are encouraged to register for the class action by July 5, 2024, to participate in potential recovery [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].